Suppr超能文献

医用大麻,对眼睑痉挛治疗有益?一项早期观察。

Medical Cannabis, a Beneficial High in Treatment of Blepharospasm? An Early Observation.

作者信息

Radke Phillip M, Mokhtarzadeh Ali, Lee Michael S, Harrison Andrew R

机构信息

Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota, USA.

Department of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA.

出版信息

Neuroophthalmology. 2017 Jul 18;41(5):253-258. doi: 10.1080/01658107.2017.1318150. eCollection 2017 Oct.

Abstract

The objective of this study was to observe the effect of medical cannabis in benign essential blepharospasm (BEB) as an adjunct to botulinum toxin. A retrospective chart review was performed on patients certified for medical cannabis use for BEB from September 2015 to May 2016. Patient demographics and responses, cannabis history, and severity indices were collected. Ten patients were certified for medical cannabis use. Five met the inclusion criteria, which was any patient with a diagnosis of BEB receiving standard botulinum toxin treatment who had started medical cannabis treatment by a registered distributor within the state, and was contactable by phone. Four patients discontinued use. Three out of four patients (75%) reported symptomatic improvement. Medical cannabis is an accepted therapy for muscle spastic disorders. Its potential as an adjunctive therapy for BEB remains unknown, and further investigations would be of benefit.

摘要

本研究的目的是观察医用大麻作为肉毒杆菌毒素辅助药物治疗良性原发性眼睑痉挛(BEB)的效果。对2015年9月至2016年5月期间因BEB而被认证可使用医用大麻的患者进行了回顾性病历审查。收集了患者的人口统计学信息和反应、大麻使用史以及严重程度指数。有10名患者被认证可使用医用大麻。其中5名符合纳入标准,即任何诊断为BEB且正在接受标准肉毒杆菌毒素治疗的患者,该患者已由该州的注册经销商开始医用大麻治疗,并且可以通过电话联系到。4名患者停止使用。4名患者中有3名(75%)报告症状有所改善。医用大麻是治疗肌肉痉挛性疾病的一种公认疗法。其作为BEB辅助治疗的潜力尚不清楚,进一步的研究将有益处。

相似文献

1
Medical Cannabis, a Beneficial High in Treatment of Blepharospasm? An Early Observation.
Neuroophthalmology. 2017 Jul 18;41(5):253-258. doi: 10.1080/01658107.2017.1318150. eCollection 2017 Oct.
2
Medical cannabis oil for benign essential blepharospasm: a prospective, randomized controlled pilot study.
Graefes Arch Clin Exp Ophthalmol. 2022 May;260(5):1707-1712. doi: 10.1007/s00417-021-05533-1. Epub 2022 Jan 24.
3
Benign essential blepharospasm among residents of Olmsted County, Minnesota, 1976 to 1995: an epidemiologic study.
Ophthalmic Plast Reconstr Surg. 2003 May;19(3):177-81. doi: 10.1097/01.iop.0000065203.88182.cf.
4
Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
Clin Exp Ophthalmol. 2010 Oct;38(7):688-91. doi: 10.1111/j.1442-9071.2010.02303.x. Epub 2010 Jul 21.
6
Effect of upper eyelid myectomy on subsequent chemodenervation in the management of benign essential blepharospasm.
Ophthalmic Plast Reconstr Surg. 2015 May-Jun;31(3):222-6. doi: 10.1097/IOP.0000000000000263.
7
Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
Clin Exp Ophthalmol. 2014 Apr;42(3):254-61. doi: 10.1111/ceo.12165. Epub 2013 Aug 4.
8
Benign essential blepharospasm: risk factors with reference to hemifacial spasm.
J Neuroophthalmol. 2005 Dec;25(4):280-5. doi: 10.1097/01.wno.0000189063.43423.04.
9
The influence of benign essential blepharospasm on dry eye disease and ocular inflammation.
Am J Ophthalmol. 2014 Mar;157(3):591-7.e1-2. doi: 10.1016/j.ajo.2013.11.014. Epub 2013 Nov 20.
10
Grey Matter Microstructural Integrity Alterations in Blepharospasm Are Partially Reversed by Botulinum Neurotoxin Therapy.
PLoS One. 2016 Dec 16;11(12):e0168652. doi: 10.1371/journal.pone.0168652. eCollection 2016.

引用本文的文献

1
Adverse Ocular Impact and Emerging Therapeutic Potential of Cannabis and Cannabinoids: A Narrative Review.
Clin Ophthalmol. 2024 Nov 29;18:3529-3556. doi: 10.2147/OPTH.S501494. eCollection 2024.
2
Therapeutic use of medical Cannabis in neurological diseases: a clinical update.
J Neural Transm (Vienna). 2024 Feb;131(2):117-126. doi: 10.1007/s00702-023-02719-1. Epub 2023 Nov 28.
3
Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm - A Randomized Pilot Study.
Transl Vis Sci Technol. 2023 Aug 1;12(8):17. doi: 10.1167/tvst.12.8.17.
4
Cannabinoids and dystonia: an issue yet to be defined.
Neurol Sci. 2020 Apr;41(4):783-787. doi: 10.1007/s10072-019-04196-5. Epub 2019 Dec 17.
5
Association between cannabis and the eyelids: A comprehensive review.
Clin Exp Ophthalmol. 2020 Mar;48(2):230-239. doi: 10.1111/ceo.13687. Epub 2019 Dec 6.

本文引用的文献

2
Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
Clin Exp Ophthalmol. 2014 Apr;42(3):254-61. doi: 10.1111/ceo.12165. Epub 2013 Aug 4.
3
Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
Am J Ophthalmol. 2013 Jul;156(1):173-177.e2. doi: 10.1016/j.ajo.2013.02.001. Epub 2013 Mar 28.
4
The pharmacologic and clinical effects of medical cannabis.
Pharmacotherapy. 2013 Feb;33(2):195-209. doi: 10.1002/phar.1187.
5
Low-dose vaporized cannabis significantly improves neuropathic pain.
J Pain. 2013 Feb;14(2):136-48. doi: 10.1016/j.jpain.2012.10.009. Epub 2012 Dec 11.
6
Multiple sclerosis and extract of cannabis: results of the MUSEC trial.
J Neurol Neurosurg Psychiatry. 2012 Nov;83(11):1125-32. doi: 10.1136/jnnp-2012-302468. Epub 2012 Jul 12.
7
Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.
CMAJ. 2012 Jul 10;184(10):1143-50. doi: 10.1503/cmaj.110837. Epub 2012 May 14.
8
Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting.
Br J Clin Pharmacol. 2010 Nov;70(5):656-63. doi: 10.1111/j.1365-2125.2010.03743.x.
10
Relationship between various clinical outcome assessments in patients with blepharospasm.
Mov Disord. 2009 Feb 15;24(3):407-13. doi: 10.1002/mds.22368.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验